Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D.
Li X, et al. Among authors: zhao r.
Br J Cancer. 2023 Sep;129(5):884-894. doi: 10.1038/s41416-023-02359-y. Epub 2023 Jul 20.
Br J Cancer. 2023.
PMID: 37474721
Free PMC article.